Overlapping Tumor Suppressor Genes Independently Involved In Melanoma - May 27 JNCI

Main Category: Melanoma / Skin Cancer
Also Included In: Genetics;  Cancer / Oncology
Article Date: 28 May 2008 - 6:00 PDT

email to a friend   printer friendly   view / write opinions   rate article

Mutations in the p14ARF tumor suppressor gene (ARF) may play a role in melanoma, independent of the effect of the p16 gene.

ARF and p16 are overlapping genes at a location on chromosome 9 that is frequently mutated in melanomas. Although researchers have previously demonstrated that inactivation of the p16 tumor suppressor gene occurs frequently in melanomas, it has been less clear whether alterations in ARF occur independently of p16 in human melanoma.

In the current study, David Polsky, M.D., Ph.D., of the New York University School of Medicine and colleagues examined the two genes in 60 metastatic melanoma tumors from 58 patients.

They found two or more alterations in the ARF gene in 26 of the tumors (43 percent) and two or more alterations in the p16 gene in 13 of the samples (22 percent). In 18 tumor samples (30 percent), ARF was inactivated in the presence of the most common form of p16.

The researchers conclude that loss of ARF can promote melanoma development, even in the presence of normal p16. "Human and mouse data provide strong evidence that ARF plays an important independent role in the pathogenesis of human melanoma," the authors write.

In an accompanying editorial, Gordon Peters, Ph.D., of Cancer Research UK London Research Institute provides a broad review of mouse and human data regarding the complex p16/ARF locus and melanoma. Although there are more data pointing to p16's role in melanoma, Peters concludes that researchers should not ignore ARF's possible contribution. "For now, we should be content to let them share the limelight," he writes.

----------------------------
Article adapted by Medical News Today from original press release.
----------------------------

Contact:

* Article: Jennifer Berman, office of communications, NYU Cancer Center, http://www.nyumc.org

Also in May 27 JNCI:

Aggressive Subclass Of Prostate Cancer May Be Driven By Estrogen Signaling

No Association Found Between Vitamin D Concentration In Blood And Risk Of Prostate Cancer

Antioxidant Supplements May Lessen Benefit Of Radiation And Chemotherapy

The Journal of the National Cancer Institute is published by Oxford University Press and is not affiliated with the National Cancer Institute. Attribution to the Journal of the National Cancer Institute is requested in all news coverage. Visit the Journal online at http://jnci.oxfordjournals.org/.

Source:
Liz Savage
Journal of the National Cancer Institute